How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat AshkenaziCNBC • 06/17/24
8 stocks other than Microsoft, Apple and Nvidia that could be worth $4 trillion in three yearsMarket Watch • 06/17/24
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.The Motley Fool • 06/16/24
Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?The Motley Fool • 06/15/24
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)Zacks Investment Research • 06/14/24
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity DrugThe Motley Fool • 06/14/24
Eli Lilly Runs Up 49% With Expectations For Weight-Loss Sales To TripleInvestors Business Daily • 06/12/24
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA AnalystBenzinga • 06/11/24